{"id":"W4414368287","doi":"10.1093/ibd/izaf163","title":"Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease","year":2025,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"UCB Pharma; AstraZeneca; Allergan; Teva Pharmaceutical Industries; Johnson and Johnson; Bristol-Myers Squibb; Akebia Therapeutics; Samsung; Genentech; Otsuka Pharmaceutical; Celltrion; Boston Pharmaceuticals; Mylan; Gilead Sciences; Sanofi; Celgene; Pfizer; Biogen; GlaxoSmithKline; Tillotts Pharma; Amgen; Dr. Falk Pharma; Celltrion Healthcare; Eli Lilly and Company","keywords":"Ustekinumab; Clinical endpoint; Immunogenicity; Disease; Inflammatory bowel disease; Clinical trial; Crohn's disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003431846,0.0005411366,0.002038695,0.0002945134,0.0002065713,0.0005414885,0.000474826,0.0005270118,0.002426973],"category_scores_gemma":[0.002837837,0.0002489205,0.001573946,0.000283941,0.0006447152,0.0005058513,0.0004113782,0.001565562,0.0003887902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004914663,"about_ca_system_score_gemma":0.00063564,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002422111,"about_ca_topic_score_gemma":0.0005935421,"domain_scores_codex":[0.9983838,0.001007449,0.00009527305,0.0001846832,0.0001529889,0.0001757905],"domain_scores_gemma":[0.9980868,0.0007792118,0.0006060341,0.0001423418,0.00008047662,0.0003050971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7546884,0.01009464,0.02593636,0.001194144,0.002141149,0.0002128033,0.000190014,0.001056606,0.007410708,0.0001822383,0.001921409,0.1949716],"study_design_scores_gemma":[0.4145782,0.5035529,0.07100203,0.0002348641,0.001657722,0.0004792608,0.00008814026,0.001551959,0.003252273,0.0002789338,0.003296216,0.000027518],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930854,0.004089862,0.0003873149,0.0002688041,0.0001041365,0.0007034679,0.0001416082,0.00004147089,0.001177935],"genre_scores_gemma":[0.9976776,0.000746067,0.0003157709,0.0002575092,0.0001031715,0.0004459331,0.0001693343,0.000004933059,0.0002797586],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003431846,"threshold_uncertainty_score":0.01814955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.002709353210720842,"score_gpt":0.2027639081542047,"score_spread":0.2000545549434838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}